1. Amy Pavlock, VMD Carlo Federici, MSc Oriana Ciani, PhD, MSc
ISPOR International Initiatives on the Assessment of the Value of Medical Technologies
Amy Pavlock, VMD
Carlo Federici, MSc
Oriana Ciani, PhD, MSc
Friday, 14 December, 2018

2. ISPOR International Initiatives on the Assessment of the Value of Medical Technologies
Objectives:
Identify the current and possible future role of HTA, cost-effectiveness and budget affordability metrics, and other tools/approaches/methods used to assess the value of medical technologies’ continuous, disruptive transformative innovation globally and locally
Present reflections on the future role that HTA and other tools could have in assessing medical technologies throughout their lifecycle to inform adoption/reimbursement or local decisions and health care policies
A long-term objective may involve building up a platform for continuous dialogue at an international level between interested stakeholders in the field of medical technologies

3. ISPOR International Initiatives on the Assessment of the Value of Medical Technologies
Methods:
Gap analysis focusing on assessment of the value of medical technologies, including the role of HTA, at different stages of the lifecycle via a systematic literature review using 2 research questions:
What is the literature on assessment of the value of medical technologies at different stages of the product lifecycle and what is the role of HTA in determining/assessing value?
Are there identifiable differences in the role of HTA assessing the value of medical devices?
Subsequent conduct of survey/mapping designed to complement the systematic overview where needed

4. ISPOR International Initiatives on the Assessment of the Value of Medical Technologies
Two reviewers from NICE UK and ISPOR independently screened the identified records
a 3rd reviewer was consulted to reconcile the differences between the initial reviewers
Preliminary data extraction from included abstracts was performed

5. Information retrieved from included papers (I)
ISPOR International Initiatives on the Assessment of the Value of Medical Technologies
Information retrieved from included papers (I)
Objective of Study
Type of Study
Country(ies)/ Region(s)
Type of Medical Technology
Medical Technology Lifecycle Stage(s)
Type of Value Assessment
The aim of the study
empirical, methodological, qualitative/surveys,
model-based
Jurisdictions where the assessment was done
Medical device, diagnostic, m-Health, etc.
Early (before market access), middle (at launch), late, whole lifecycle
Formal HTA, clinical performance, economic performance, broaden societal impact etc.

6. Information retrieved from included papers (II)
ISPOR International Initiatives on the Assessment of the Value of Medical Technologies
Information retrieved from included papers (II)
Organization Performing Value Assessment
Type(s) of Evidence Collected
Methods used for assessment
Conclusions
Limitations
Name and type of organization (HTA agency, SHI, private companies etc.)
Clinical effectiveness, performance, safety, costs, etc.
MCDA, modelling, mixed methods etc.
Summary of conclusions relating to value assessment of MDs, barriers and facilitating factors
Limitation of the study

7. ISPOR International Initiatives on the Assessment of the Value of Medical Technologies
Preliminary results (I)

8. ISPOR International Initiatives on the Assessment of the Value of Medical Technologies
Preliminary results (II)

9. ISPOR International Initiatives on the Assessment of the Value of Medical Technologies
Preliminary results (III) Conclusions:
Growing experience and literature in the assessment of the value for medical technologies
Most of the studies are commentaries unspecific with respect to type of technologies, stage of lifecycle development, geographic region
More applied studies refer directly to high income setting, device/diagnostics types of products, and early stage of development
Wide scope raises challenges in focus for this review

10. ISPOR International Initiatives on the Assessment of the Value of Medical Technologies
Next Steps:
Ultimate full-text data extraction and provide a critical overview of methods and roles of value assessment framework in the literature
Invite additional international agencies, individuals, and/or regions to participate in this project
Conduct interviews to integrate the results of the review
Provide policy recommendations on the future role that HTA and other tools could have in assessing medical technologies

11. Thank you for your attention.
Acknowledgments
Thank you for your attention.
Adriana Velazquez Berumen
Carlo Federici, MSc
Finn Børlum Kristensen, MD, PhD
Giuditta Callea, PhD
Julie Polisena, PhD, MSc
Leandro Pecchia, PhD
Mirella Marlow, MBA, MA
Oriana Ciani, PhD, MSc
Øyvind Melien, MD, PhD, MSc

12. Disclosure
No funding has been supplied for this project and there are no conflicts of interest for any participants.